Ticker brief

EWTX

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
5
crowd 14d
-0.8σ

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d109%HV n/a
Skew — 25Δ RR 30d-0.08925Δ call IV − put IV
OI alarmquietlast alarm 2026-06-16 (z=2.6)
Sentiment — last 14 days
daily mean sentiment, 2026-10-08 → 2026-10-16 · now +0.40 (−1 bearish … +1 bullish)
Who spoke5
authorgradetrader scoresignalsmean sent
@OzmosiHealthC·2+0.10
@CrweWorldC·1+0.15
@HunterAllen4C-2.091+0.20
@semodoughC-1.061-0.25
@Quantumup1C+0.101+0.40
Recent signals6of 6 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-10-16@Quantumup1+0.40William Blair initiated Edgewise at Outperform with a $53 valuation and identified multiple clinical catalysts.·
2026-10-14@semodough-0.25B. Riley reiterates a Buy view and $146 target on CYTK with multiple near-term catalysts.·
2026-10-12@HunterAllen4+0.20Presents a detailed long-term bullish thesis for SBIO as diversified exposure to clinical-stage biotech.·
2026-10-09@OzmosiHealth+0.00Edgewise scheduled Phase 1 healthy-volunteer results for EDG-15400 on Oct. 12.·
2026-10-08@OzmosiHealth+0.20Company dosed the first patient in a Phase 2 trial.·
2026-10-08@CrweWorld+0.15Reports dosing of the first patient in Edgewise's Phase 2 EQUINOX-HFpEF trial.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.